The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
Open accessAbstract
Purpose: Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow-up and reported the clinical response of four additional patients with MET-amplified tumors to the small molecule inhibitor crizotinib as part of an expanded phase I cohort study. Patients and Methods: From 2007 to 2009, patients with GEC were genetically screened as a consecutive series of 489 tumors (stages 0, I, and II, 39%; III, 25%; IV, 36%; n = 222 esophageal, including n = 21 squamous carcinomas). MET, EGFR, and HER2 amplification status was assessed by using fluorescence in situ hybridization. Results: Ten (2%) of 489 patients screened harbored MET amplification; 23 (4.7%) harbored EGFR amplification; 45 (8.9%) harbored HER2 amplification; and 411 (84%) were wild type for all three genes (ie, negative). MET-amplified tumors were typically high-grade adenocarcinomas that presented at advanced stages (5%; n = 4 of 80). EGFR-amplified tumors showed the highest fraction of squamous cell carcinoma (17%; n = 4 of 23). HER2, MET, and EGFR amplification were, with one exception (MET and EGFR positive), mutually exclusive events. Survival analysis in patients with stages III and IV disease showed substantially shorter median survival in MET/EGFR-amplified groups, with a rank order for all groups by median survival (from most to least aggressive): MET (7.1 months; P < .001) less than EGFR (11.2 months; P = .16) less than HER2 (16.9 months; P = .89) when compared with the negative group (16.2 months). Two of four patients with MET-amplified tumors treated with crizotinib experienced tumor shrinkage (−30% and −16%) and experienced progression after 3.7 and 3.5 months. Conclusion: MET amplification defines a small and aggressive subset of GEC with indications of transient sensitivity to the targeted MET inhibitor crizotinib (PF-02341066).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,475
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, Jr., Al-Sarraf, M., Byhardt, R., Russell, A. H., Beitler, J. J., Spencer, S., et al. (1999) · JAMA · doi:10.1001/jama.281.17.1623 · Cited by 1,957
Pathology and Genetics of Tumours of the Digestive System
(2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01219.x · Cited by 1,314
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Self-citationTanner, M., Hollmén, M., Junttila, T. T., Kapanen, A. I., Tommola, S., Soini, Y., Helin, H., Salo, J., Joensuu, H., Sihvo, E., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi064 · Cited by 665
Rüdiger Siewert, J., Feith, M., Werner, M., & Stein, H. J. (2000) · Annals of Surgery · doi:10.1097/00000658-200009000-00007 · Cited by 662
Christensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0365 · Cited by 649
Self-citationSmolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 485
Self-citationShah, M. A., Ramanathan, R. K., Ilson, D. H., Levnor, A., D'Adamo, D., O'Reilly, E., Tse, A., Trocola, R., Schwartz, L., Capanu, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0887 · Cited by 406
Acdonald, J. O. S. M., Malley, R., Acqueline, J., Undahl, S. C. A. H., Orman, N., Stes, C. E., Temmermann, G. R. N. S., Aller, D. A. G. H., Affer, J., Jani, A., et al. (2012) · Cited by 402
Frequent amplification of the c-met gene in scirrhous type stomach cancer
Kuniyasu, H., Yasui, W., Kitadai, Y., Yokozaki, H., Ito, H., & Tahara, E. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91548-5 · Cited by 328
Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127
Dragovich, T., McCoy, S., Fenoglio-Preiser, C. M., Wang, J., Benedetti, J. K., Baker, A. F., Hackett, C. B., Urba, S. G., Zaner, K. S., Blanke, C. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1316 · Cited by 311
Kim, M. A., Lee, H. S., Lee, H. E., Jeon, Y. K., Yang, H. K., & Kim, W. H. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03021.x · Cited by 283
Qi, J., McTigue, M. A., Rogers, A., Lifshits, E., Christensen, J. G., Jänne, P. A., & Engelman, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1623 · Cited by 216
Self-citationSun, W., Powell, M., O'Dwyer, P. J., Catalano, P., Ansari, R. H., & Benson, A. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7988 · Cited by 214
Shah, M. A., Jhawer, M., Ilson, D. H., Lefkowitz, R. A., Robinson, E., Capanu, M., & Kelsen, D. P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0770 · Cited by 186
Hara, T., Ooi, A., Kobayashi, M., Mai, M., Yanagihara, K., & Nakanishi, I. (1998) · PubMed · Cited by 183
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Cepero, V., Sierra, J. R., Corso, S., Ghiso, E., Casorzo, L., Perera, T., Comoglio, P. M., & Giordano, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0436 · Cited by 167
Gene amplification in gastric and esophageal adenocarcinomas.
Houldsworth, J., Cordon‐Cardo, C., Ladanyi, M., Kelsen, D. P., & Chaganti, R. S. K. (1990) · PubMed · Cited by 156
METExpression and Amplification in Patients with Localized Gastric Cancer
Janjigian, Y. Y., Tang, L. H., Coit, D. G., Kelsen, D. P., Francone, T. D., Weiser, M. R., Jhanwar, S. C., & Shah, M. A. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1080 · Cited by 151
Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
Weiner, L. M., Belldegrun, A. S., Crawford, J., Tolcher, A. W., Lockbaum, P., Arends, R., Navale, L., Amado, R. G., Schwab, G. M., & Figlin, R. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1509 · Cited by 136
Okines, A. F. C., Ashley, S. E., Cunningham, D., Oates, J. R., Turner, A., Webb, J., Saffery, C., Chua, Y. J., & Chau, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2847 · Cited by 132
Enzinger, P. C., Burtness, B. A., Niedzwiecki, D., Ye, X., Douglas, K., Ilson, D. H., Villaflor, V. M., Cohen, S. J., Mayer, R. J., Venook, A. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5092 · Cited by 112
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
Wei, Q., Chen, L., Sheng, L., Nordgren, H., Wester, K., & Carlsson, J. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.3.493 · Cited by 81
The HGF Receptor c-Met Is Overexpressed in Esophageal Adenocarcinoma
Herrera, L. J., El‐Hefnawy, T., de Oliveira, P. E. Q., Raja, S., Finkelstein, S. D., Gooding, W. E., Luketich, J. D., Godfrey, T. E., & Hughes, S. J. (2005) · Neoplasia · doi:10.1593/neo.04367 · Cited by 62
木村, 幹., Tsuda, H., Morita, D., Ichikura, T., Ogata, S., Aida, S., Yoshizumi, Y., Maehara, T., Mochizuki, H., & Matsubara, O. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1048-7 · Cited by 60
Role of c-Met in Cancer: Emphasis on Lung Cancer
Salgia, R. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.02.008 · Cited by 57
Self-citationHirono, Y., Tsugawa, K., Fushida, S., et al. (2009) · Oncology · doi:10.1159/000227455 · Cited by 47
Wang, Y., Sheu, B., Yang, H.-B., Lin, P., & Chang, Y. (2002) · PubMed · Cited by 29
Combined Modality Therapy of Esophageal Cancer
Juergens, R. A., & Forastiere, A. A. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0063 · Cited by 17
Javeri, H., Arora, R., Correa, A. M., Hofstetter, W. L., Lee, J. H., Liao, Z. X., McAleer, M. F., Maru, D. M., Bhutani, M. S., Swisher, S. G., et al. (2008) · Cancer · doi:10.1002/cncr.23688 · Cited by 16
Adenocarcinomas on the Rise — Does it Influence Survival from Oesophageal Cancer?
Goscinski, M. A., Larsen, S. G., Warloe, T., Stoldt, S., Nesland, J. M., Suo, Z., & Giercksky, K. E. (2009) · Scandinavian Journal of Surgery · doi:10.1177/145749690909800404 · Cited by 12
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796
Self-citationAmplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A.-M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 539
Metadata
- Authors
- Lennerz, J. K., Kwak, E. L., Ackerman, A., Michael, M., Fox, S. B., Bergethon, K., Lauwers, G. Y., Christensen, J. G., Wilner, K. D., Haber, D. A., Salgia, R., Bang, Y.-J., Clark, J. W., Solomon, B. J., & Iafrate, A. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-12-20
- Volume
- 29
- Issue
- 36
- Pages
- 4803-4810
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127401934
- Cited by
- 433
- References
- 38
- FWCI
- 36.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.